PV Reporter

04/27/2026

Eli Lilly is expanding its footprint in the blood cancer space with the acquisition of Ajax Therapeutics.

This move is centered on advancing new, targeted therapies for patients living with myelofibrosis and polycythemia vera. It’s an exciting step forward for innovation in hematology! 🧬

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. ("Ajax"), a biopharmaceutical company developing next generation JAK inhibitors...

04/24/2026

🔬 Big news for ET patients with a CALR mutation.
A first-in-class antibody, INCA033989, is rapidly normalizing platelet counts and shrinking the mutant clone in most patients treated. FDA Breakthrough Therapy designation granted December 2025. Phase 3 planned for mid-2026.
From ASH 2025 (ET cohort):
• ~90% hematologic response at higher doses
• 83% complete hematologic response
• Most patients saw their CALR mutant clone shrink
• No dose-limiting toxicities
No existing ET therapy reliably reduces the CALR mutant clone. This one does.
📖 https://pvreporter.com/breakthrough-calr-therapy-shows-high-response-rate-in-et/

* This replaces my earlier post with tighter numbers from the ASH 2025 abstract.

Incyte’s INCA033989 targets CALR mutations in ET patients, delivering high response rates and potential disease modification with minimal side effects.

04/20/2026

The MPN community lost one of its greatest champions this week.

Dr. Richard T. Silver passed away on April 17, 2026, at the age of 97. For those of us living with polycythemia vera or another MPN, his name means everything. though many may not even know it yet.

He helped write the rules of modern hematology. He trained the doctors who treat us today. He founded a cancer research charity that has given away $17 million. He explored the Amazon. He played the clarinet.

And he never stopped caring about patients.
I had the privilege of meeting him in person in 2023. I wrote this piece to make sure our community knows who he was, and what we owe him.

Rest in peace, Dr. Silver. 🙏

Dr. Richard T. Silver, the Weill Cornell hematologist who introduced interferon for MPNs and helped launch imatinib for CML, has died at 97. A tribute.

04/17/2026

🚨 Major news for the Essential Thrombocythemia community!

Alethio Therapeutics just unveiled ATX-011, a first-of-its-kind antibody that works regardless of your mutation (JAK2, CALR, or MPL). In animal studies, it normalized platelet counts within days with zero myelosuppression and no safety signals, a stark contrast to Hydroxyurea, which takes months, often fails, and carries a 13% skin cancer risk.

They're targeting an IND filing in Q1 2027 with clinical proof-of-concept data expected by H1 2028.

After many years of an outdated standard of care, the ET community may finally have something better on the horizon. We'll be watching this one closely. 🧬

With Besremi also pursuing ET approval, competition in this space is heating up, and patients may soon have real options beyond a 50-year-old chemotherapy drug.

https://alethiotherapeutics.com/news-events/

04/15/2026

New research in Leukemia (Nature) supports my recent video:

👉 Early interferon in PV may lead to deep remission
👉 Some patients may even reach an “operational cure”

For years, “watch and wait” was the norm.
That may be changing.
As you know, I’m in remission.
But I believe it can be more, and the science is starting to support that.
https://www.nature.com/articles/s41375-026-02882-w

04/04/2026

I've been reading through your comments on yesterday's video, and honestly, thank you so much! The support, encouragement, and the personal stories you've shared mean more than you know.

Rather than replying one by one, I'm going to record a follow-up video when I get back hopefully in the next week or so to speak to some of the bigger questions that came up, and things we're working on behind the scenes to make PV Reporter better, while adding new resources.

👊 One thing I do want to address now. Medically, I'm in remission. I understand that. But mindset matters Alot. I choose to see this as my cure, and I truly believe that plays a real role in how I show up every day.

We're in this together. More soon and Happy Easter. ❤️

04/03/2026

04/03/2026

Remission is possible, and self-advocacy is your best medicine! 🏖️

I may have gone a little long in this one (blame the Cherry Grove breeze, and the last beer), but this felt too important not to share. You're managing blood counts isn't enough!

Here's the truth: as patients, we have to be our own biggest advocates. Doing your own research isn't optional. It's essential. The standard path of Hydroxyurea or repeated phlebotomies alone simply isn't enough if the goal is true remission.

I'm a strong believer in the interferons because I've lived the results. After 16+ years as a PV patient (and 13 years of well informed advocacy), I'm standing here today in complete remission for 6 years!! That's not luck. That's informed advocacy,

I want every person in our community to have the knowledge they need to fight for the best possible outcome. Remission isn't just a dream. It's a reality I'm living right now.
Keep sharing. Keep learning. Keep pushing for better.

Wishing everyone a wonderful, healthy Easter weekend!

04/01/2026

Are you seeing the right doctor for your MPN?

Most hematologists don't specialize in myeloproliferative neoplasms. And that can impact your care.

We created a simple resource to help you:
• Identify true MPN specialists
• Find treatment centers with real experience
• Take the next step with confidence

If you or someone you love is living with an MPN, start here.

Explore our website for the latest on MPN Specialist in the U.S. Doctor-reviewed and regularly updated, we offer valuable resources for your health journey.

03/20/2026

Abstract: Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis

Ruxolitinib and subsequent JAK2 inhibitors have improved care for some patients with the myeloproliferative neoplasms myelofibrosis, essential thrombocythe

03/17/2026

📰 Metformin Reduces BM Fibrosis and JAK-STAT Signaling in PMF

Metformin associated w/ reductions in bone marrow fibrosis, downregulation of key oncogenic signaling pathways in pts w/ primary myelofibrosis.

03/11/2026

I’m excited to share a new resource with the MPN community! The MPN Clinical Trial Finder is now live in BETA and available for everyone to use. 🚀

David Wallace, your PV Reporter, created this tool to serve our community and make the process of finding relevant clinical trials easier. It is completely free, and I’ve designed it so that no personal information is required to use it.

Check it out here: https://pvreporter.com/mpn-clinical-trial-finder/

A quick tip: If you receive a "nothing found" message, try clearing some of the search fields or refreshing your screen to reset the parameters. Please take a look and let me know your feedback, as I work to refine things as needed.